Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | RNMT | O43148 | 1/20 | 0.31 |
| ▸ | GAPDH | P04406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665982 | 0.93 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL1667985 | 0.93 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL5558224 | 0.88 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL29881527 | 0.88 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL1096766 | 0.88 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL25727 | 0.87 | TYMP (0.33) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL1665732 | 0.86 | P2RY6 (0.35) | — | |
| SCHEMBL1667971 | 0.86 | P2RY6 (0.35) | — | |
| SCHEMBL1935584 | 0.86 | TYMP (0.37) | TYMP | |
| SCHEMBL1666138 | 0.86 | TYMP (0.37) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314594-B1 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8022193-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2314594-A1 | 6-modified bicyclic nucleic acid analogs | Isis Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1984381-B1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100216979-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741457-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7399845-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070249049-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | FOUNDATION MEDICINE, INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | TYMP 93/4885PRMT6 627/4885ADORA2A 264/4885 |
| US-20070249049-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | TYMP 93/4885PRMT6 627/4885ADORA2A 264/4885 |
| US-20100216979-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | TYMP 93/4885PRMT6 627/4885ADORA2A 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.